Trial Profile
A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Tucatinib (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms DB-07; DESTINY-Breast07
- Sponsors AstraZeneca; AstraZeneca AB
- 06 Jun 2023 Planned End Date changed from 30 Dec 2025 to 2 Jul 2025.
- 06 Jun 2023 Planned primary completion date changed from 26 Feb 2025 to 31 Jan 2025.
- 06 Jun 2023 Status changed from recruiting to active, no longer recruiting.